Nextleaf Solutions Ltd. (CSE:OILS) is pleased to announce that it has been issued a patent by the United States Patent and Trade Office pertaining to the Company’s proprietary process of extraction, refinement, and distillation of cannabinoids from marijuana and hemp.

The resulting THC or CBD distillate is tasteless, odourless, standardized for potency, and ready to use in a wide range of products, including topicals, transdermal or sublingual delivery technology, vape technology, edible oils, beverages, and water-soluble extracts. Nextleaf’s patented technology allows for low-quality dried cannabis biomass to be efficiently processed into a high-purity distilled oil, simplifying the manufacturing of differentiated cannabinoid formulations and delivery methods.

Nextleaf is pleased to further announce that it has been issued a standard patent by IP Australia – the Australian Government agency that administers intellectual property (“IP”) rights – for the Company’s unique, industrial-scale process of producing purified cannabinoid distillate.

The Company’s management believes, to the best of its knowledge, that Nextleaf is the first publicly traded company to be issued a patent for the extraction and purification of cannabinoids.

“Nextleaf Solutions has succeeded in beating big pharma, big tobacco, big alcohol, and every single billion-dollar cannabis company to the first issued patent for the extraction and purification of cannabinoids.” said Paul Pedersen, CEO. “We believe companies that can develop and protect valuable intellectual property will benefit substantially in the long-term, especially in an industry as young as the cannabis industry.

Currently, legal cannabis producers in Canada can only sell one form of cannabis extract (“cannabis oil”) with a maximum potency of approximately 3% THC. However, the Federal Government has announced that cannabis concentrates, edibles, beverages, topicals, and vape pens will be legal by October 2019, and is expected to publish draft regulations in the coming months. These products are extremely popular in other legal cannabis jurisdictions, and demand for them continues to grow.

“Nextleaf’s patented process allows a cannabis processor to turn raw biomass or a crude extract into a refined, high-purity oil that’s tasteless, odourless, easy to standardize, or even make water soluble. Developed by Nextleaf’s team of chemists and engineers, it allows us to efficiently separate and isolate THC and CBD molecules at an industrial scale, before reformulating in the ideal combination based on the product, client, and end consumer’s needs. The mass-market consumer is looking for a consistent experience to either reliably target a particular medical condition, or to bring about a desired effect. We expect Nextleaf’s issued patent will have a major impact on the production of the next generation of legal cannabis products, especially since most federally-legal cannabis processors seem to be lacking the technology and expertise to do it themselves,” said Nextleaf Co-Founder and CEO Paul Pedersen.

Nextleaf’s patented process improves upon traditional extraction methods that use only CO2 or ethanol to produce crude cannabis extracts. Unrefined botanical extracts contain chlorophyll, fats, and other impurities that result in undesirable flavours and aromas when consumed. Nextleaf’s unique method of extracting and separating cannabinoids and terpenes makes it possible to purify and concentrate the desired compounds, which can be used for the manufacturing of a diverse array of products standardized for dose.

The Company initially files its patents in the United States to create a priority date and allow for future filings in other selected jurisdictions. This is common in the field of IP protection. Following the issuance of its patent in the United States, Nextleaf filed for patent protection in Canada, Europe, Mexico, Colombia, and Jamaica. These patent filings are part of the Company’s overall strategy to develop and protect IP pertaining to the production of innovative cannabinoid-based products geared towards both medical cannabis patients and adult-use consumers.

About Nextleaf Solutions

Nextleaf Solutions Ltd. (CSE: OILS) is an extraction technology company that has developed a portfolio of issued and pending patents pertaining to the company’s unique, industrial-scale process of producing purified cannabinoid distillate, a tasteless, odourless cannabis concentrate best suited for infusing premium value-added products. Nextleaf plans to commercialize its intellectual property portfolio by providing B2B processing services to licensed cultivators and supplying cannabis oil and extracts to qualified Canadian and international partners under the client’s own brands. Nextleaf has completed construction of its dedicated extraction and processing facility in Greater Vancouver, British Columbia, in time for Canada’s legalization of edibles and other cannabis derivative products. The Company’s processing facility includes research and laboratory infrastructure, allowing for the continued development of novel, scalable cannabis processing technology and intellectual property.

For more information about Nextleaf Solutions (CSE: OILS) visit  www.nextleafsolutions.com or follow Nextleaf across social media platforms.

Contacts

Adel Fares, Investor Relations
604-283-2301 (ext. 201)
investors@nextleafsolutions.com

Paul Pedersen, CEO
604-347-9160
paul@nextleafsolutions.com

CAUTIONARY STATEMENT:
The securities described herein, if any, have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and may not be offered or sold within the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any of Nextleaf Solutions securities in the United States. This news release may contain “forward-looking information” as defined in applicable Canadian securities legislation. All statements other than statements of historical fact included in this release, including, without limitation, future operating margins, future production and processing, processing results, and future plans and objectives of Nextleaf Solutions, constitute forward looking information that involve various risks and uncertainties. Forward-looking information is based on a number of factors and assumptions which have been used to develop such information but which may prove to be incorrect, including, but not limited to, assumptions in connection with the continuance of Nextleaf Solutions and its subsidiaries as a going concern, general economic and market conditions, price of biomass, the accuracy of production resource estimates, and the performance of Nextleaf Solutions future operations. There can be no assurance that such information will prove to be accurate and actual results and future events could differ materially from those anticipated in such forward-looking information. Important factors that could cause actual results to differ materially from Nextleaf Solutions’ expectations include but are not limited to: changes in economic conditions or financial markets; increases in costs; litigation; legislative, environmental and other judicial, regulatory, political and competitive developments; and technological or operational difficulties. This list is not exhaustive of the factors that may affect our forward-looking information. These and other factors should be considered carefully, and readers should not place undue reliance on such forward-looking information. For additional information with respect to risk factors applicable to Nextleaf Solutions, reference should be made to Nextleaf Solutions continuous disclosure materials filed from time to time with securities regulators, including, but not limited to, Nextleaf Solutions CSE Listing Statement. The forward-looking information contained in this release is made as of the date of this release. Nextleaf Solutions does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable law. The CSE has not reviewed, approved or disapproved the contents of this press release. To contact the company, email investors@nextleafsolutions.com

Related Links

https://www.nextleafsolutions.com

Click here to connect with Nextleaf Solutions Ltd. (CSE:OILS) for an Investor Presentation. 

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less